成人B细胞淋巴母细胞白血病（B-ALL）中，约一半未达到分子完全缓解或随后复发的患者无法被目前的化疗或靶向治疗治愈。过去，这些患者唯一的治疗选择是造血干细胞移植。最近，几种免疫治疗，包括单克隆抗体、双特异性T细胞诱导剂（BiTEs）、抗体药物联合物（ADCs）和嵌合抗原受体T细胞（CARs），在这个领域已被证明是安全和有效的。在本文中，我们总结了美国FDA批准的包括利妥昔单抗、布林妥珂单抗、伊诺珠单抗克雷松、替嗪蛋白和布瑞细胞自体淋巴细胞疗法在内的先进成人B-ALL的免疫治疗数据。我们考虑了临床试验中关于疗效、安全性以及生活质量（QoL）的结果。还介绍了现实世界中的证据。我们还简要讨论了药效学、药动学和药经济学，随后进行了风险-效益分析。最后，我们介绍了成人B-ALL免疫治疗未来的方向。版权所有©2023 Elsevier Ltd.

About one-half of adults with acute B-cell lymphoblastic leukemia (B-ALL) who do not achieve molecular complete remission or who subsequently relapse are not cured by current chemo- or targeted therapies. Previously, the sole therapeutic option for such persons was a hematopoietic stem cell transplant. Recently, several immune therapies including monoclonal antibodies, bispecific T-cell engagers (BiTEs), antibody-drug conjugates (ADCs), and chimeric antigen receptor T-cells (CARs) have been shown safe and effective in this setting. In this manuscript, we summarize data on US FDA-approved immune therapies of advanced adult B-ALL including rituximab, blinatumomab, inotuzumab ozogamicin, tisagenlecleucel and brexucabtagene autoleucel. We consider the results of clinical trials focusing on efficacy, safety, and quality of life (QoL). Real-world evidence is presented as well. We also briefly discuss pharmacodynamics, pharmacokinetics, and pharmacoeconomics followed by risk-benefit analyses. Lastly, we present future directions of immune therapies for advanced B-ALL in adults.Copyright © 2023. Published by Elsevier Ltd.